Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 9/20 | 0.42 |
| ▸ | RORC | P51449 | 3/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.39 |
| ▸ | GNRHR | P30968 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 3/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26969772 | 0.92 | NPY5R (0.41) | NPY5RACLYGNRHRTACR1PRSS1 | |
| SCHEMBL26969741 | 0.86 | NPY5R (0.40) | NPY5RACLYGNRHRTACR1PRSS1 | |
| SCHEMBL26969711 | 0.85 | NPY5R (0.42) | NPY5RACLYGNRHRTACR1PRSS1 | |
| SCHEMBL26969733 | 0.81 | NPY5R (0.60) | NPY5RTACR1PRSS1PRSS2PRSS3 | |
| SCHEMBL26969704 | 0.81 | NPY5R (0.43) | NPY5RGNRHRTACR1 | |
| SCHEMBL26969717 | 0.81 | NPY5R (0.41) | NPY5RACLYGNRHRTACR1PRSS1 | |
| SCHEMBL26969740 | 0.80 | HTT (0.49) | NPY5RACLYNAMPT | |
| SCHEMBL26969775 | 0.80 | NPC1L1 (0.42) | NPY5RGNRHRTACR1 | |
| SCHEMBL26969778 | 0.79 | NPY5R (0.49) | NPY5RTACR1PRSS1PRSS2PRSS3 | |
| SCHEMBL26969732 | 0.79 | NPY5R (0.47) | NPY5RGNRHRTACR1PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | NPY5R 681/4885RORC 2737/4885ACLY 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.